Does the media favor PHVS or PTGX?

In the previous week, Protagonist Therapeutics had 10 more articles in the media than Pharvaris. MarketBeat recorded 15 mentions for Protagonist Therapeutics and 5 mentions for Pharvaris. Protagonist Therapeutics' average media sentiment score of 1.18 beat Pharvaris' score of 0.70 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is SYRE or PHVS more profitable?

Spyre Therapeutics' return on equity of -30.74% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Pharvaris N/A -67.56% -61.13%

Does the media refer more to SYRE or PHVS?

In the previous week, Spyre Therapeutics had 18 more articles in the media than Pharvaris. MarketBeat recorded 23 mentions for Spyre Therapeutics and 5 mentions for Pharvaris. Spyre Therapeutics' average media sentiment score of 0.85 beat Pharvaris' score of 0.70 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 10 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KYMR or PHVS?

In the previous week, Kymera Therapeutics had 7 more articles in the media than Pharvaris. MarketBeat recorded 12 mentions for Kymera Therapeutics and 5 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.70 beat Kymera Therapeutics' score of 0.51 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, PHVS or QGEN?

Qiagen has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Qiagen $2.09B 4.11 $424.88M $1.91 21.84

Is PHVS or QGEN more profitable?

Qiagen has a net margin of 19.49% compared to Pharvaris' net margin of 0.00%. Qiagen's return on equity of 14.24% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Qiagen 19.49% 14.24% 8.23%

Does the media favor PHVS or QGEN?

In the previous week, Qiagen had 12 more articles in the media than Pharvaris. MarketBeat recorded 17 mentions for Qiagen and 5 mentions for Pharvaris. Qiagen's average media sentiment score of 0.77 beat Pharvaris' score of 0.70 indicating that Qiagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, TGTX or PHVS?

TG Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 12.31 $447.18M $2.74 18.08 Pharvaris N/A N/A -$198.79M -$3.18 N/A

Is TGTX or PHVS more profitable?

TG Therapeutics has a net margin of 55.22% compared to Pharvaris' net margin of 0.00%. TG Therapeutics' return on equity of 73.23% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 55.22% 73.23% 37.22% Pharvaris N/A -67.56% -61.13%

Does the media refer more to TGTX or PHVS?

In the previous week, TG Therapeutics had 29 more articles in the media than Pharvaris. MarketBeat recorded 34 mentions for TG Therapeutics and 5 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.70 beat TG Therapeutics' score of 0.10 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Pharvaris 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pharvaris (PHVS) Competitors

$34.45 +1.03 (+3.08%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$34.74 +0.29 (+0.84%)

As of 04:00 AM Eastern

Compare

PHVS vs. PTGX, SYRE, KYMR, QGEN, and TGTX

Should you buy Pharvaris stock or one of its competitors? MarketBeat compares Pharvaris with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pharvaris include Protagonist Therapeutics (PTGX), Spyre Therapeutics (SYRE), Kymera Therapeutics (KYMR), Qiagen (QGEN), and TG Therapeutics (TGTX).

How does Pharvaris compare to Protagonist Therapeutics?

Pharvaris (NASDAQ:PHVS) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Protagonist Therapeutics has a net margin of 29.40% compared to Pharvaris' net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.98% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Protagonist Therapeutics	29.40%	12.98%	12.03%

Protagonist Therapeutics has higher revenue and earnings than Pharvaris. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Protagonist Therapeutics	$46.02M	204.28	-$130.15M	-$1.81	N/A

Pharvaris has a beta of -2.31, suggesting that its share price is 331% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

Pharvaris currently has a consensus target price of $50.08, suggesting a potential upside of 45.38%. Protagonist Therapeutics has a consensus target price of $126.71, suggesting a potential downside of 13.32%. Given Pharvaris' higher probable upside, equities analysts plainly believe Pharvaris is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Protagonist Therapeutics had 10 more articles in the media than Pharvaris. MarketBeat recorded 15 mentions for Protagonist Therapeutics and 5 mentions for Pharvaris. Protagonist Therapeutics' average media sentiment score of 1.18 beat Pharvaris' score of 0.70 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Pharvaris on 14 of the 16 factors compared between the two stocks.

How does Pharvaris compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Pharvaris (NASDAQ:PHVS) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 11.8% of Pharvaris shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Spyre Therapeutics' return on equity of -30.74% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Pharvaris	N/A	-67.56%	-61.13%

Spyre Therapeutics has a beta of 3.03, suggesting that its share price is 203% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.31, suggesting that its share price is 331% less volatile than the broader market.

Spyre Therapeutics currently has a consensus target price of $110.15, indicating a potential upside of 6.51%. Pharvaris has a consensus target price of $50.08, indicating a potential upside of 45.38%. Given Pharvaris' higher probable upside, analysts clearly believe Pharvaris is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

In the previous week, Spyre Therapeutics had 18 more articles in the media than Pharvaris. MarketBeat recorded 23 mentions for Spyre Therapeutics and 5 mentions for Pharvaris. Spyre Therapeutics' average media sentiment score of 0.85 beat Pharvaris' score of 0.70 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	10 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has higher revenue and earnings than Pharvaris. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	10,218.83	-$155.20M	-$1.95	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

Summary

Spyre Therapeutics beats Pharvaris on 12 of the 14 factors compared between the two stocks.

How does Pharvaris compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Pharvaris (NASDAQ:PHVS) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

In the previous week, Kymera Therapeutics had 7 more articles in the media than Pharvaris. MarketBeat recorded 12 mentions for Kymera Therapeutics and 5 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.70 beat Kymera Therapeutics' score of 0.51 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	223.24	-$311.35M	-$3.57	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

Kymera Therapeutics presently has a consensus target price of $125.65, indicating a potential upside of 18.08%. Pharvaris has a consensus target price of $50.08, indicating a potential upside of 45.38%. Given Pharvaris' higher probable upside, analysts clearly believe Pharvaris is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Pharvaris has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.82% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.82%	-19.66%
Pharvaris	N/A	-67.56%	-61.13%

Kymera Therapeutics has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.31, indicating that its stock price is 331% less volatile than the broader market.

Summary

Kymera Therapeutics and Pharvaris tied by winning 7 of the 14 factors compared between the two stocks.

How does Pharvaris compare to Qiagen?

Pharvaris (NASDAQ:PHVS) and Qiagen (NYSE:QGEN) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Qiagen had 12 more articles in the media than Pharvaris. MarketBeat recorded 17 mentions for Qiagen and 5 mentions for Pharvaris. Qiagen's average media sentiment score of 0.77 beat Pharvaris' score of 0.70 indicating that Qiagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has a beta of -2.31, suggesting that its stock price is 331% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

Pharvaris presently has a consensus price target of $50.08, indicating a potential upside of 45.38%. Qiagen has a consensus price target of $42.43, indicating a potential upside of 1.72%. Given Pharvaris' stronger consensus rating and higher probable upside, research analysts plainly believe Pharvaris is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

Qiagen has a net margin of 19.49% compared to Pharvaris' net margin of 0.00%. Qiagen's return on equity of 14.24% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Qiagen	19.49%	14.24%	8.23%

70.0% of Qiagen shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Qiagen has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Qiagen	$2.09B	4.11	$424.88M	$1.91	21.84

Summary

Qiagen beats Pharvaris on 11 of the 15 factors compared between the two stocks.

How does Pharvaris compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Pharvaris (NASDAQ:PHVS) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, TG Therapeutics had 29 more articles in the media than Pharvaris. MarketBeat recorded 34 mentions for TG Therapeutics and 5 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.70 beat TG Therapeutics' score of 0.10 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Pharvaris	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	12.31	$447.18M	$2.74	18.08
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

TG Therapeutics presently has a consensus price target of $58.67, indicating a potential upside of 18.40%. Pharvaris has a consensus price target of $50.08, indicating a potential upside of 45.38%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts plainly believe Pharvaris is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

58.6% of TG Therapeutics shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TG Therapeutics has a net margin of 55.22% compared to Pharvaris' net margin of 0.00%. TG Therapeutics' return on equity of 73.23% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.23%	37.22%
Pharvaris	N/A	-67.56%	-61.13%

TG Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.31, suggesting that its share price is 331% less volatile than the broader market.

Summary

TG Therapeutics beats Pharvaris on 10 of the 16 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHVS vs. The Competition

Export

Metric	Pharvaris	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.19B	$3.61B	$6.95B	$12.87B
Dividend Yield	N/A	3.76%	2.59%	9.93%
P/E Ratio	-10.83	8.36	271.11	25.30
Price / Sales	N/A	1,285.72	600.09	82.38
Price / Cash	N/A	101.37	71.89	50.37
Price / Book	7.31	17.72	13.05	6.13
Net Income	-$198.79M	-$13.22M	$3.46B	$342.95M
7 Day Performance	5.61%	4.44%	3.43%	3.19%
1 Month Performance	-0.40%	-4.89%	-2.65%	-1.98%
1 Year Performance	69.54%	56.61%	76.02%	21.11%

Pharvaris Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHVS Pharvaris	3.6292 of 5 stars	$34.45 +3.1%	$50.08 +45.4%	+62.3%	$2.19B	N/A	N/A	30	Upcoming Earnings
PTGX Protagonist Therapeutics	1.7926 of 5 stars	$136.84 +0.9%	$123.00 -10.1%	+171.6%	$8.80B	$46.02M	N/A	120	Positive News Earnings Report Analyst Forecast Gap Up
SYRE Spyre Therapeutics	2.6085 of 5 stars	$99.91 -0.1%	$101.42 +1.5%	+548.0%	$8.79B	N/A	N/A	73	Trending News Earnings Report Analyst Forecast Insider Trade
KYMR Kymera Therapeutics	1.9927 of 5 stars	$106.16 -3.5%	$124.68 +17.4%	+157.3%	$8.73B	$51.48M	N/A	170	Trending News Earnings Report Analyst Forecast
QGEN Qiagen	3.7385 of 5 stars	$42.16 +2.6%	$43.34 +2.8%	-16.5%	$8.69B	$2.10B	22.02	5,654	Trending News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHVS) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharvaris (PHVS) Competitors

PHVS vs. PTGX, SYRE, KYMR, QGEN, and TGTX

How does Pharvaris compare to Protagonist Therapeutics?

Summary

How does Pharvaris compare to Spyre Therapeutics?

Summary

How does Pharvaris compare to Kymera Therapeutics?

Summary

How does Pharvaris compare to Qiagen?

Summary

How does Pharvaris compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS vs. The Competition

Pharvaris Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharvaris (PHVS) Competitors

PHVS vs. PTGX, SYRE, KYMR, QGEN, and TGTX

How does Pharvaris compare to Protagonist Therapeutics?

Do institutionals & insiders have more ownership in PHVS or PTGX?

Is PHVS or PTGX more profitable?

Which has higher valuation and earnings, PHVS or PTGX?

Which has more volatility and risk, PHVS or PTGX?

Do analysts recommend PHVS or PTGX?

Does the media favor PHVS or PTGX?

Summary

How does Pharvaris compare to Spyre Therapeutics?

Do insiders and institutionals believe in SYRE or PHVS?

Is SYRE or PHVS more profitable?

Which has more volatility and risk, SYRE or PHVS?

Do analysts recommend SYRE or PHVS?

Does the media refer more to SYRE or PHVS?

Which has stronger earnings & valuation, SYRE or PHVS?

Summary

How does Pharvaris compare to Kymera Therapeutics?

Does the media refer more to KYMR or PHVS?

Which has preferable earnings and valuation, KYMR or PHVS?

Do analysts rate KYMR or PHVS?

Is KYMR or PHVS more profitable?

Which has more volatility & risk, KYMR or PHVS?

Summary

How does Pharvaris compare to Qiagen?

Does the media favor PHVS or QGEN?

Which has more risk and volatility, PHVS or QGEN?

Do analysts rate PHVS or QGEN?

Is PHVS or QGEN more profitable?

Do insiders & institutionals believe in PHVS or QGEN?

Which has stronger earnings & valuation, PHVS or QGEN?

Summary

How does Pharvaris compare to TG Therapeutics?

Does the media refer more to TGTX or PHVS?

Which has preferable valuation and earnings, TGTX or PHVS?

Do analysts rate TGTX or PHVS?

Do institutionals & insiders believe in TGTX or PHVS?

Is TGTX or PHVS more profitable?

Which has more volatility & risk, TGTX or PHVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS vs. The Competition

Pharvaris Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools